What Are Recursion Pharmaceuticals Inc.'s Key Financial Figures?
| Fiscal year | FY2025 ended December 31, 2025 | FY2024 ended December 31, 2024 | FY2023 ended December 31, 2023 | FY2022 ended December 31, 2022 |
|---|---|---|---|---|
| Revenue | $75 million | $59 million | $45 million | $40 million |
| Operating income | -$648 million | -$479 million | -$350 million | -$246 million |
| Operating margin | -867.9% | -814.1% | -785.3% | -616.7% |
| Net income | -$645 million | -$464 million | -$328 million | -$239 million |
| Net margin | -863.4% | -788.0% | -736.0% | -601.0% |
| Operating cash flow | -$372 million | -$359 million | -$288 million | -$84 million |
| Capital expenditures | $6 million | $14 million | $12 million | $37 million |
| Free cash flow | -$378 million | -$373 million | -$300 million | -$121 million |
Operating margin narrowed by 53.8 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$378 million against net income of -$645 million; cash generation covered reported earnings.
What Does Recursion Pharmaceuticals Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $743 million |
|---|---|
| Long-term debt | $10 million |
| Total assets | $1.5 billion |
| Total liabilities | $343 million |
| Shareholders' equity | $1.1 billion |
| Current ratio | 5.5x |
Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Recursion Pharmaceuticals Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001601830-26-000039 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Recursion Pharmaceuticals Inc.'s revenue in fiscal 2025?
Recursion Pharmaceuticals Inc. reported revenue of $75 million for the fiscal year ended December 31, 2025, according to its SEC filings.
What is Recursion Pharmaceuticals Inc.'s operating margin?
Recursion Pharmaceuticals Inc.'s operating margin was -867.9% in fiscal 2025: operating income of -$648 million on revenue of $75 million.
How much free cash flow did Recursion Pharmaceuticals Inc. generate?
Operating cash flow of -$372 million less capital expenditures of $6 million gives free cash flow of -$378 million for fiscal 2025.